article thumbnail

HPM’s Larry Houck Presenting at WCF Opioid and Fentanyl Abuse Management Congress

The FDA Law Blog

Houck One of the most significant issues facing hospitals and other facilities is the diversion of controlled substances meant for patients by physicians, pharmacists, nurses and other trusted healthcare employees.

article thumbnail

Thank You for an Illuminating Experience

Omnicell

Omnicell Illuminate gave us the opportunity to strengthen relationships by understanding shared experiences, learning best practices, and engaging in workshops to evolve medication management strategies to advance toward the ultimate goal – the zero-error pharmacy.

article thumbnail

FDA Takes Another Small Step to Increase Naloxone Access

The FDA Law Blog

Naloxone is a prescription drug, but unlike some other prescription drugs used in the treatment of opioid addiction such as buprenorphine , it is not a controlled substance. Because naloxone is a prescription drug, its distribution is subject to the requirements of the Drug Supply Chain Security Act (DSCSA).

FDA